<SEC-DOCUMENT>0000950170-23-009051.txt : 20230322
<SEC-HEADER>0000950170-23-009051.hdr.sgml : 20230322
<ACCEPTANCE-DATETIME>20230322083559
ACCESSION NUMBER:		0000950170-23-009051
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230322
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230322
DATE AS OF CHANGE:		20230322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inozyme Pharma, Inc.
		CENTRAL INDEX KEY:			0001693011
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				475129768
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39397
		FILM NUMBER:		23751514

	BUSINESS ADDRESS:	
		STREET 1:		321 SUMMER STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-330-4340

	MAIL ADDRESS:	
		STREET 1:		321 SUMMER STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Inozyme Pharma, LLC
		DATE OF NAME CHANGE:	20161222
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>inzy-20230322.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-21T18:01:52.7017+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:inzy="http://www.inozyme.com/20230322">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_c889c58d-1e95-4dd3-a53b-8119b92ef87e" name="dei:EntityCentralIndexKey" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d">0001693011</ix:nonNumeric><ix:nonNumeric id="F_bce39a01-2b43-4c75-a7e3-4b2c3c8867ee" name="dei:AmendmentFlag" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="inzy-20230322.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-22</xbrli:startDate><xbrli:endDate>2023-03-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.25pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_15d433dc-fe23-4987-82cd-2d10f6f66126" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_70054b86-5dfb-4f4b-9089-790a2bffee0f" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 22, 2023</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4c36094e-7cff-4c94-830f-61e368274066" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INOZYME PHARMA, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:41.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0e2aba63-0200-4645-bf4f-dcfe0ad27061" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ec942db4-19f1-4369-8ed0-3f159fa26251" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39397</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_83f3bff4-7fde-4c13-b023-7231768fd455" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38-4024528</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_20f8bb15-ee05-4a89-98d1-782b4999b346" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">321 Summer Street</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6b5664d1-a5cf-47bb-9981-1c8699833e0d" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 400</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fcf54d65-b816-465d-8ada-7b537fb45c76" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ffb954f3-86d5-4991-98a6-788746de6bfa" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_852db5a4-34bb-42ec-bfc0-24899a7e9018" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02210</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code: (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bb2bcd57-bc32-4a78-86ed-dfbf0774e280" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_868dac40-d34e-4384-ad0d-e2ad88a0bab6" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">330-4340</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be86bf49-0a2b-4f6d-8195-534d46cd93e0" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7380ed0e-eb6e-4512-b6f9-1d8884eb7489" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ca45aaa-f8c0-4f94-b07b-5ec3b949d96d" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d9b736f-d993-460b-98a8-ce31b4db1d35" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_95e16892-4774-414a-88cd-8e0fdfed46aa" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2afca189-e515-4da0-95e4-a6b1c2199d8e" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INZY</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bb93b2b9-e732-4eef-903b-fdfbf9673c2e" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_2b751dba-6b35-4849-ab84-5565fbbee083" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_e8cbaeb5-1b67-4591-b080-b4a7c3bd661d" contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double rgba(0,0,0,1);text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 22, 2023, Inozyme Pharma, Inc. (the &#x201c;Company&#x201d;) announced its financial results for the year ended December 31, 2022. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d) Exhibits:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following exhibit is furnished herewith:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.037%;"></td>
    <td style="width:1.981%;"></td>
    <td style="width:90.981%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.1</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="inzy-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Press Release issued by the Company on March 22, 2023</span></a></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.0%;"></td>
    <td style="width:44.0%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:46.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INOZYME PHARMA, INC.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Axel Bolte</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Axel Bolte<br />Title: President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>inzy-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img4202433_0.jpg" alt="img4202433_0.jpg" style="width:178px;height:89px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">- Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed as CEO -</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">- Matthew Winton, Ph.D., appointed COO -</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">- Upcoming clinical and regulatory milestones remain on track with previous guidance -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">- Current cash, cash equivalents and short-term investments anticipated to fund cash flow requirement into the fourth quarter of 2024 -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">BOSTON, Mar. 22, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2022, and provided recent business highlights. The Company also today announced that founding chief executive officer (CEO), Axel Bolte, MSc, MBA, will retire from his current role and that Douglas A. Treco, Ph.D., chairman of the Company&#x2019;s board of directors (Board), will succeed Mr. Bolte as the CEO of the Company, effective April 1, 2023.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x201c;With the recent release of positive topline data for INZ-701 in the ongoing ENPP1 Deficiency and ABCC6 Deficiency trials, the planned initiation of pivotal trials this year, and a strong cash balance, Inozyme is well-positioned for its next chapter. After more than seven years leading Inozyme from concept to Phase 3 readiness, I am excited to pass the baton to Doug to lead the Company into late-stage clinical development and pre-commercial activities,&#x201d; said Mr. Bolte. &#x201c;Doug&#x2019;s experience as a leader of multiple rare disease companies and deep knowledge of our team and science uniquely positions him to lead Inozyme and further unlock its potential value. I look forward to assisting the Company and Doug in this next phase.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x201c;The Board and I are immensely grateful for Axel&#x2019;s leadership and accomplishments from forming the Company to advancing its lead programs to Phase 3 readiness. I look forward to continuing to benefit from his experience as a Senior Advisor and Board member,&#x201d; said Dr. Treco. &#x201c;Throughout my career, I have been driven to make a difference for patients living with rare disease and I believe INZ-701 is a unique product candidate which has the potential to transform the treatment of multiple severe disorders.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Recent Management Updates</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">CEO Transition. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Axel Bolte, MSc, MBA, the Company&#x2019;s founding CEO will retire and continue to work with Inozyme as a senior advisor and serve on the Board. Douglas A. Treco, Ph.D., an industry veteran and Chairman of the Board, will succeed Mr. Bolte as </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the CEO of the Company, effective April 1, 2023. Dr. Treco was co-founder, president, and chief executive officer of Ra Pharmaceuticals, Inc. (acquired in 2020 by UCB S.A. for $2.5 billion) where he oversaw the discovery and development of zilucoplan in myasthenia gravis, which is currently under review for marketing approval in the United States and European Union. Previously, he co-founded Transkaryotic Therapies, Inc. (TKT; acquired in 2005 by Shire plc), where he directed research and development efforts which led to the approval of Replagal&#174;, Elaprase&#174;, Dynepo&#153;, and Vpriv&#174;. Dr. Treco is a member of the Board of Directors of CRISPR Therapeutics AG.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">COO Appointment. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Matthew Winton, Ph.D. has been appointed chief operations officer, effective April 3, 2023. Dr. Winton most recently served as senior vice president and head of the Multiple Sclerosis franchise for Biogen&#x2019;s US organization. Previously, he was the head of Biogen&#x2019;s Spinal Muscular Atrophy franchise in the US, where he was responsible for setting strategic direction for the infant, pediatric, and adult markets. Matt also served as director, Payer and Channel Marketing at Biogen, where he was responsible for the development and execution of pricing, access, and reimbursement strategies across various therapeutic franchises. In particular, he helped successfully prepare the organization for the approval and launch of its first orphan disease drug, SPINRAZA&#153;. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x201c;Matt&#x2019;s extensive strategic and commercial experience in rare diseases will be critical as we plan to execute our pivotal trials in ENPP1 Deficiency and continue to develop the market opportunity across our indications. We are excited to begin working with him,&#x201d; added Dr. Treco.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Recent Clinical and Regulatory Updates</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Expanded Access Program (EAP).</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> The Company recently dosed the first pediatric patient with ENPP1 Deficiency with INZ-701 under its EAP.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Regulatory Progress.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> The Company has initiated discussions with the U.S. Food and Drug Administration (FDA) regarding the design and clinical endpoints for pivotal trials in ENPP1 Deficiency. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phase 1/2 Clinical Trial of INZ-701 in Adults with ENPP1 Deficiency.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> The Company recently announced positive topline pharmacokinetic (PK), pharmacodynamic (PD) and safety data and encouraging patient reported outcome data from the ongoing trial. Dosing is ongoing in the Phase 2 portion of the trial and the Company is on track to report interim clinical data in the third quarter of 2023. The Company also plans to investigate the potential for once-weekly dosing in the ongoing trial.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phase 1/2 Clinical Trial of INZ-701 in Adults with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE).</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> The Company recently announced positive topline PK, PD and safety </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">data from the ongoing trial. Dosing is ongoing in the Phase 2 portion of the trial and the Company is on track to report interim clinical data in the fourth quarter of 2023.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Calciphylaxis Program.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> The Company recently received allowance of its investigational new drug (IND) application from the FDA to evaluate INZ-701 in a clinical trial in patients with end stage kidney disease (ESKD) and calciphylaxis.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Anticipated Milestones in 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ENPP1 Deficiency</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Initiation of ENERGY-1 - Phase 1b clinical trial to evaluate the safety, tolerability, PK and PD of INZ-701 in infants&#x2014;Q2 2023</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interim clinical data from ongoing Phase 1/2 trial in adults&#x2014;Q3 2023</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Initiation of pivotal trial in pediatric patients, subject to regulatory approval&#x2014;Q3 2023</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Start of European Medicines Agency protocol assistance meetings&#x2014;Q4 2023</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ABCC6 Deficiency</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interim clinical data from ongoing Phase 1/2 trial in adults&#x2014;Q4 2023</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Financial Results for the Year Ended December 31, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cash Position and Financial Guidance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#x2013; Cash, cash equivalents, and short-term investments were $127.9 million as of December 31, 2022. Based on its current plans, the Company anticipates its cash, cash equivalents, and short-term investments as of December 31, 2022, together with the additional $20.0 million borrowed on February 15, 2023 under its existing debt facility, will enable the Company to fund cash flow requirements into the fourth quarter of 2024.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research and Development (R&amp;D) Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#x2013; R&amp;D expenses were $47.8 million for the year ended December 31, 2022, compared to $37.7 million for the year ended December 31, 2021. This increase was primarily due to an increase in clinical trial costs due to the progression of the clinical trials of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency, costs for consultants to support our ongoing trials, and personnel-related costs, partially offset by a decrease in research costs.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General and Administrative (G&amp;A) Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#x2013; G&amp;A expenses were $20.8 million for the year ended December 31, 2022, compared to $18.9 million for the year ended December 31, 2021. The increase was primarily due to an increase in personnel costs.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net Loss</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#x2013; Net loss was $67.1 million, or $1.78 loss per share, for the year ended December 31, 2022, compared to $56.6 million, or $2.40 loss per share, for the year ended December 31, 2021.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About ENPP1 Deficiency</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ENPP1 Deficiency is a progressive condition that manifests as a spectrum of diseases. Individuals who present in utero or in infancy are typically diagnosed with generalized arterial calcification of infancy (GACI), which is characterized by extensive vascular calcification and intimal proliferation (overgrowth of smooth muscle cells inside blood vessels), resulting in myocardial infarction, stroke, or cardiac or multiorgan failure. Approximately 50% of infants with ENPP1 Deficiency die within six months of birth. Children with ENPP1 Deficiency typically experience rickets, a condition also known as autosomal-recessive hypophosphatemic rickets type 2 (ARHR2), while adults experience osteomalacia (softened bones), and they can exhibit a range of signs and symptoms that include hearing loss, arterial calcification, and cardiac and/or neurological involvement. There are no approved therapies for ENPP1 Deficiency.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The ongoing Phase 1/2 open-label clinical trial initially enrolled nine adult patients with ENPP1 Deficiency at sites in North America and Europe. The trial is designed to primarily assess the safety and tolerability of INZ-701 in adult patients with ENPP1 Deficiency, as well as characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of INZ-701, including evaluation of plasma pyrophosphate (PPi) and other biomarker levels. In the Phase 1 dose-escalation portion of the trial, Inozyme assessed INZ-701 for 32-days at doses of 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection with three patients per dose cohort. Patients received a single dose and then began twice weekly dosing one week later. Doses were selected based on preclinical studies and PK/PD modeling. The Phase 1 dose-escalation portion of the trial was designed to identify a safe, tolerable dose that increases PPi levels, and that can be used for further clinical development. The open-label Phase 2 portion of the trial is assessing long-term safety, pharmacokinetics, and pharmacodynamics of continued treatment with INZ-701 for up to 48 weeks, where patients may receive doses of INZ-701 at home depending on site-specific protocols. Exploratory endpoints include evaluations of ectopic calcification, skeletal, vascular, and physical function, patient-reported outcomes, and exploratory biomarkers.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About ABCC6 Deficiency</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ABCC6 Deficiency is a rare, severe, inherited disorder caused by mutations in the ABCC6 gene, leading to low levels of PPi. PPi is essential for preventing harmful soft tissue calcification and regulating bone mineralization. ABCC6 Deficiency is a systemic and progressively debilitating condition, which affects more than 67,000 individuals worldwide. Infants with ABCC6 Deficiency are diagnosed with generalized arterial calcification of infancy (GACI) type 2, a condition that resembles GACI type 1, the infant form of ENPP1 Deficiency. In older individuals, ABCC6 Deficiency presents as pseudoxanthoma elasticum (PXE), which is characterized by pathological mineralization in blood vessels and soft tissues clinically affecting the skin, eyes, and vascular system. There are no approved therapies for ABCC6 Deficiency.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The ongoing Phase 1/2 open-label clinical trial initially enrolled nine adult patients with ABCC6 Deficiency at sites in the United States and Europe. The trial is designed to primarily assess the safety and tolerability of INZ-701 in adult patients with ABCC6 Deficiency, as well as characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of INZ-701, including the evaluation of levels of plasma PPi and other biomarkers. In the Phase 1 dose-escalation portion of the trial, Inozyme assessed INZ-701 for 32-days at doses of 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection with three patients per dose cohort. Patients received a single dose and then began twice weekly dosing one week later. Doses were selected based on preclinical studies and PK/PD modeling. The Phase 1 dose-escalation portion of the trial was designed to identify a safe, tolerable dose for further development that increases PPi levels. The open-label Phase 2 portion of the trial is assessing long-term safety, pharmacokinetics, and pharmacodynamics of continued treatment with INZ-701 for up to 48 weeks, where patients may receive doses of INZ-701 at home depending on site-specific protocols. Exploratory endpoints include evaluations of ectopic calcification, vascular and retinal function, patient- reported outcomes and exploratory biomarkers.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About INZ-701</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">INZ-701 is a clinical-stage enzyme therapy in development for the treatment of rare disorders of the vasculature, soft tissue, and skeleton. In preclinical studies, the experimental therapy has shown potential to prevent pathologic mineralization and intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels), which can drive morbidity and mortality in devastating genetic disorders such as ENPP1 Deficiency and ABCC6 Deficiency. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of adult ENPP1 Deficiency and ABCC6 Deficiency.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About Inozyme Pharma</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. We are developing INZ-701, an enzyme therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For more information, please visit www.inozyme.com and follow us on </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">LinkedIn</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Twitter</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, and </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Facebook</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#34;forward- looking statements&#34; within the meaning of The Private Securities Litigation Reform Act of 1995.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">These statements include, but are not limited to, statements relating to the timing of our planned clinical trials, the availability of data from clinical trials, timing of planned regulatory meetings, the potential benefits of INZ-701, and the sufficiency of the Company's cash resources. The words &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;should,&#34; &#34;target,&#34; &#34;will,&#34; &#34;would,&#34; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's ability to conduct its ongoing Phase 1/2 clinical trials of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain, and protect intellectual property rights related to its product candidates; manage expenses; comply with the covenants under its outstanding loan agreement; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the &#34;Risk Factors&#34; section in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors, in the Company's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Condensed Consolidated Balance Sheet Data</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(Unaudited)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(in thousands)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:87.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.857%;"></td>
    <td style="width:26.538%;"></td>
    <td style="width:25.605%;"></td>
   </tr>
   <tr style="height:22.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:19.3pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:19.3pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.3104166666666667in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,</font></p><p style="margin-left:19.3pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.3104166666666667in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.9pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:22.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.20833333333333334in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,</font></p><p style="margin-left:22.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.20833333333333334in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</font></p></td>
   </tr>
   <tr style="height:16.55pt;">
    <td style="background-color:rgba(207,239,251,1);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cash, cash equivalents and investments</font></p></td>
    <td style="background-color:rgba(207,239,251,1);text-indent:9.65pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:9.65pt;text-indent:0.0pt;font-size:11.0pt;margin-top:5.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	127,866</font></p></td>
    <td style="background-color:rgba(207,239,251,1);text-indent:13.3pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:13.3pt;text-indent:0.0pt;font-size:11.0pt;margin-top:5.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	111,801</font></p></td>
   </tr>
   <tr style="height:16.55pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total assets</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:9.65pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:9.65pt;text-indent:0.0pt;font-size:11.0pt;margin-top:5.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	139,195</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:13.3pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:13.3pt;text-indent:0.0pt;font-size:11.0pt;margin-top:5.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	123,541</font></p></td>
   </tr>
   <tr style="height:16.55pt;">
    <td style="background-color:rgba(207,239,251,1);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="background-color:rgba(207,239,251,1);text-indent:9.65pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:9.65pt;text-indent:0.0pt;font-size:11.0pt;margin-top:5.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	20,801</font></p></td>
    <td style="background-color:rgba(207,239,251,1);text-indent:13.3pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:13.3pt;text-indent:0.0pt;font-size:11.0pt;margin-top:5.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	14,273</font></p></td>
   </tr>
   <tr style="height:16.55pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Additional paid-in-capital</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:9.65pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:9.65pt;text-indent:0.0pt;font-size:11.0pt;margin-top:5.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	333,356</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:13.3pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:13.3pt;text-indent:0.0pt;font-size:11.0pt;margin-top:5.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	256,948</font></p></td>
   </tr>
   <tr style="height:16.55pt;">
    <td style="background-color:rgba(207,239,251,1);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accumulated deficit</font></p></td>
    <td style="background-color:rgba(207,239,251,1);text-indent:9.65pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:9.65pt;text-indent:0.0pt;font-size:11.0pt;margin-top:5.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	(214,761)</font></p></td>
    <td style="background-color:rgba(207,239,251,1);text-indent:13.3pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:13.3pt;text-indent:0.0pt;font-size:11.0pt;margin-top:5.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	(147,700)</font></p></td>
   </tr>
   <tr style="height:16.55pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total stockholders' equity</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:9.65pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:9.65pt;text-indent:0.0pt;font-size:11.0pt;margin-top:5.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	118,394</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:13.3pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:13.3pt;text-indent:0.0pt;font-size:11.0pt;margin-top:5.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	109,268</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(Unaudited)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(in thousands, except share and per share data)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.276%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:19.724%;"></td>
   </tr>
   <tr style="height:12.95pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);text-indent:273.15pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:273.15pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;Year Ended December 31,</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:1.35pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.08888888888888889in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:6.5pt;text-indent:0.0pt;font-size:11.0pt;margin-top:1.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;2021</font></p></td>
   </tr>
   <tr style="height:12.95pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;Operating expenses:</font></p></td>
   </tr>
   <tr style="height:15.85pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:25.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25.35pt;text-indent:0.0pt;font-size:11.0pt;margin-top:1.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research and development</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:34.45pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:34.45pt;text-indent:0.0pt;font-size:11.0pt;margin-top:3.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	47,849</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:11.9pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	37,720</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(207,239,251,1);text-indent:25.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25.35pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General and administrative</font></p></td>
    <td style="background-color:rgba(207,239,251,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.1638888888888889in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;20,826</font></p></td>
    <td style="background-color:rgba(207,239,251,1);text-indent:34.45pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="margin-left:34.45pt;text-indent:0.0pt;font-size:11.0pt;margin-top:3.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">18,926</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.08888888888888889in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;68,675</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:6.5pt;text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;56,646</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(207,239,251,1);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="background-color:rgba(207,239,251,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.16319444444444445in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(68,675)</font></p></td>
    <td style="background-color:rgba(207,239,251,1);text-indent:27.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="margin-left:27.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(56,646)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other income (expense):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(207,239,251,1);text-indent:25.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25.35pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interest income, net</font></p></td>
    <td style="background-color:rgba(207,239,251,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.1638888888888889in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,933</font></p></td>
    <td style="background-color:rgba(207,239,251,1);text-indent:48.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:48.35pt;text-indent:0.0pt;font-size:11.0pt;margin-top:3.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">211</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:25.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25.35pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other expense, net</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:2.95pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.08888888888888889in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;(319)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:6.5pt;text-indent:0.0pt;font-size:11.0pt;margin-top:2.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;(189)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(207,239,251,1);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other income, net</font></p></td>
    <td style="background-color:rgba(207,239,251,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.1638888888888889in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,614</font></p></td>
    <td style="background-color:rgba(207,239,251,1);text-indent:53.95pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="margin-left:53.95pt;text-indent:0.0pt;font-size:11.0pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">22</font></p></td>
   </tr>
   <tr style="height:17.3pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net loss</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.55pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.08888888888888889in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;$	(67,061)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:6.5pt;text-indent:0.0pt;font-size:11.0pt;margin-top:3.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;$  (56,624)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(207,239,251,1);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other comprehensive (loss) income:</font></p></td>
    <td style="background-color:rgba(207,239,251,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,239,251,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:25.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25.35pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unrealized (losses) on available-for-sale securities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.1638888888888889in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(198)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:52.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:52.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:3.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(4)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(207,239,251,1);text-indent:25.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25.35pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Foreign currency translation adjustment</font></p></td>
    <td style="background-color:rgba(207,239,251,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:2.95pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.16319444444444445in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(25)</font></p></td>
    <td style="background-color:rgba(207,239,251,1);text-indent:53.95pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="margin-left:53.95pt;text-indent:0.0pt;font-size:11.0pt;margin-top:2.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total other comprehensive (loss) income</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.08888888888888889in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;(223)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:6.5pt;text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;16</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(207,239,251,1);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Comprehensive loss</font></p></td>
    <td style="background-color:rgba(207,239,251,1);text-indent:17.5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="margin-left:17.5pt;text-indent:0.0pt;font-size:11.0pt;margin-top:4.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	(67,284)</font></p></td>
    <td style="background-color:rgba(207,239,251,1);text-indent:11.9pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:4.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$  (56,608)</font></p></td>
   </tr>
   <tr style="height:29.5pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.35pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.12361111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net loss attributable to common stockholders&#x2014;basic and diluted</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.08888888888888889in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;$	(67,061)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.5pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;$  (56,624)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:26.65pt;">
    <td style="background-color:rgba(207,239,251,1);text-indent:5.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.35pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net loss per share attributable to common stockholders&#x2014;basic and diluted</font></p></td>
    <td style="background-color:rgba(207,239,251,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:17.5pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	(1.78)</font></p></td>
    <td style="background-color:rgba(207,239,251,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$	(2.40)</font></p></td>
   </tr>
   <tr style="height:27.35pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.35pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-average common shares outstanding&#x2014;basic and diluted</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.08888888888888889in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;37,763,168</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:5.75pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;23,558,306</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Contacts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Investors:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inozyme Pharma</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stefan Riley, Director of IR and Corporate Communications</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(857) 330-8871</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">stefan.riley@inozyme.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Media:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">SmithSolve</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Matt Pera</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(973) 886-9150</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">matt.pera@smithsolve.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img4202433_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img4202433_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "? 3X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M60-.JA?-1P=I('&[*MG&!TKT&L#PEX1T[P=I366G^9(9'\R:>4@O(V,<XP
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ML1*#PS ]01THH22FVQU5[NA>^&__ "1SQ?\ [UU_Z3)7C4O^H?\ W3_*O??
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M\1Z)'%&H1$6]B 4 8  STKP'_A6'C;_H7YO_  (A_P#BZ/\ A6'C;_H7YO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>inzy-20230322.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-21T18:01:52.6302+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.inozyme.com/20230322" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:inzy="http://www.inozyme.com/20230322" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inzy-20230322_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inzy-20230322_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>inzy-20230322_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-21T18:01:52.7192+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>inzy-20230322_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-21T18:01:52.7082+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="inzy-20230322.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140031897971024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 22,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOZYME PHARMA, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001693011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-39397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-4024528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">321 Summer Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">330-4340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INZY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>inzy-20230322_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="inzy-20230322.xsd" xlink:type="simple"/>
    <context id="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2023-03-22</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_c889c58d-1e95-4dd3-a53b-8119b92ef87e">0001693011</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_bce39a01-2b43-4c75-a7e3-4b2c3c8867ee">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_15d433dc-fe23-4987-82cd-2d10f6f66126">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_70054b86-5dfb-4f4b-9089-790a2bffee0f">2023-03-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_4c36094e-7cff-4c94-830f-61e368274066">INOZYME PHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_0e2aba63-0200-4645-bf4f-dcfe0ad27061">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_ec942db4-19f1-4369-8ed0-3f159fa26251">001-39397</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_83f3bff4-7fde-4c13-b023-7231768fd455">38-4024528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_20f8bb15-ee05-4a89-98d1-782b4999b346">321 Summer Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_6b5664d1-a5cf-47bb-9981-1c8699833e0d">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_fcf54d65-b816-465d-8ada-7b537fb45c76">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_ffb954f3-86d5-4991-98a6-788746de6bfa">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_852db5a4-34bb-42ec-bfc0-24899a7e9018">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_bb2bcd57-bc32-4a78-86ed-dfbf0774e280">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_868dac40-d34e-4384-ad0d-e2ad88a0bab6">330-4340</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_be86bf49-0a2b-4f6d-8195-534d46cd93e0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_7380ed0e-eb6e-4512-b6f9-1d8884eb7489">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_8ca45aaa-f8c0-4f94-b07b-5ec3b949d96d">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_2d9b736f-d993-460b-98a8-ce31b4db1d35">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_95e16892-4774-414a-88cd-8e0fdfed46aa">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_2afca189-e515-4da0-95e4-a6b1c2199d8e">INZY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_bb93b2b9-e732-4eef-903b-fdfbf9673c2e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_2b751dba-6b35-4849-ab84-5565fbbee083">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_38dafdc5-ebce-4870-aa35-692fee0c4b2d"
      id="F_e8cbaeb5-1b67-4591-b080-b4a7c3bd661d">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MR&>XCSQFS;'#)0/JDQGT'E!-X#+42PRT=G\?]V\4=+Z1C:"XY*P0D"P=S\,
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( 'Q$=E8ZJJ+G0 $  #P"   /
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M-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$%     @ ?$1V5B0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( 'Q$=E9ED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !\1'96#G!:L.X    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !\1'96
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( 'Q$=E8(PSJ[C00  -,1   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !\1'96
MGZ ;\+$"  #B#   #0              @ '0#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( 'Q$=E:7BKL<P    !,"   +              "  :P/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( 'Q$=E8ZJJ+G0 $  #P"   /
M      "  940  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !\1'96)!Z;
MHJT   #X 0  &@              @ $"$@  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !\1'9699!YDAD!  #/ P  $P
M    @ 'G$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   Q
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="inzy-20230322.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="inzy-20230322.htm">inzy-20230322.htm</File>
    <File>inzy-20230322.xsd</File>
    <File>inzy-20230322_lab.xml</File>
    <File>inzy-20230322_pre.xml</File>
    <File>inzy-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "inzy-20230322.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "inzy-20230322.htm"
     ]
    },
    "labelLink": {
     "local": [
      "inzy-20230322_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "inzy-20230322_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "inzy-20230322.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "inzy",
   "nsuri": "http://www.inozyme.com/20230322",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "inzy-20230322.htm",
      "contextRef": "C_38dafdc5-ebce-4870-aa35-692fee0c4b2d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "inzy-20230322.htm",
      "contextRef": "C_38dafdc5-ebce-4870-aa35-692fee0c4b2d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-23-009051-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-009051-xbrl.zip
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M?H3(D)!-,"#_/$&9&(RBG,0\&671!&4D%UDX437+"@D%J!5G \K\<NE]E@P
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MDT&F#WRN8WR7KT(K!FD'X]\RX: ,-_,Q53%EKVO'^9L_&K[!%F_VDB036:#
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MGP/V!O,S/@8>Y4FKV$1<&TKO@T(?XB?(9O!_'+Q,^$;1 ;T?D(%$1&X36"%
M#-XP5P%'.!Z+F%@T1V8!FQ2Z9H[3/X6CER5NTV#9.>/D!=\2=Q%@AT"S ?@1
MIR49S6H,3%]&P9R<,E())J)E^$)$["94MX'PAX0JH*"Q1   2/'SS,AI*/],
M13!EV5&@$!CG$,A@BS\9H(('"TC#0(&%@X<5*<14W"8HE2GLY#T+E+K!P[Q%
MI@O# (2E3O"<RM#$\0C4A)W2'GN$)];(P%1=/N(XZJ9S5%1N2 <@3 2V '0D
M@69#C;0P!,5+@"Y%3 DUEX(H#1'JD8P,G_.0Z@*I1\9P(AX$OQK/(SQ2@C]!
MM0V^0-(A\@)%#.8:ZX7L:A$UX4YDF-+HBO5%""P[*52G>99Q+4*)6_ G4L/_
MN&*SZS&IA7,<Z3RVNE7!D3Z-X'"'(Y4F;#P%9AX+^!6L:\1!Y/0%\&(_ELB2
M835C?@/3 CL"#2FF-2#X0.&5!)H V" LFQPC,WS+G$!?!!(X:2&V</V&.R&8
M_-1#0Q9T31!P@@$2>2-8A>'>!1M"8S0&-, CN*]\YWP3Q8A9@8KQ.!W/V7&>
ML[Z([I51V3[P$+0&0L1?(T3ABH1D*XAJOIS,)NW4<9$GG4:GT_GN]!YX@(A!
M0YV># )Q=Q\T?Z2@? RFV9ST%&IP<7)* *C#5L?ZI ^,"-7GA> J5E]>0U6%
MXAP"Y*?QP$',P#0'J P1(G6"ZX/SSJ/< S O@[+;[1VWCEO=@U;SL'/<^RX3
MS^UVCA$E5)A=U6;S!/0K?$(Q11IW@RT*QFV:9K4DSK_((3,H)0C,N(!0$[ :
M#AJT[%;%-I*2VR&H%6BCU?"25@-K0Y^3,75)Q6DL]QB!'0G(#D@:3]E$@(')
MC??M[9PGB<9YR$>4,R[ 4_NO8^5E5CZ*LX5$(/WJ?5#&;NH<;?H3'MSRJ:Y&
MRN5C('9_TB>SW>?+/R?\GG\*P$1D7P8RF9Z,I ]PK8XXK(087*?0>*R3O3!1
MV2WP7T_529:@30IKUQ*/S#@@EX4C8*8K;L-!63Q'9W$A[E%@$UV=.%^3]:?L
MU[=OV'4#9 @:L]^V&P<,D"4 L;T/1B@:D>A;!6M2\UO: QR0A^^GU@M7. =A
MZK]DD'H*':HXQ7C*-?PDE!P]#H"'-6O7%D&08,IH?PPS"0"C<!% I3>"/&H\
MPD@.F+W6Q_MK2([-ZP3M"YK_(HU5)& Z^ HUC4N;D1  D$>B *!O])$;'D\5
MP 2#/X 'Z+2TH/GTTZ=3-@N?Y@'"YWJ$DCL*/(RF9  QD18*,(&-'\.6YH$!
M)TR9K6;#@7''XA[R/>%)"0#5D ? )GM=P*B+@$<Q,*OL_?DT%)&"=P>=4W/L
M_PWH,C%?EY&%G G&YS$CW/'->1X5@C=OK]Y?7U[9[=LXWMF/#2?HG<U6,;%5
M&2&U*S;;+[^ ,*(<2F1@VV&T+<P5);<J^7:+G%$C3D&4F)0$G<G3^Z*Z4Q;5
M9EPV5CJQL4L0:&2K44ZW->0F,%(AOXF/XPVNC%-_R+RVUUX@8J4ENMEY"$O2
MQL7\1JJA" O[\M=KIN(A#VUFQ3VI=VO=QMDD\[^_CF0( NA#JKTTX#$[2T"(
MCJ:E63-Y>UV2>3@J["$"Z,A^8%:F14*"&DQ-$,F8]&$D(\90LYP-&0XX:BV1
M\"5/8NG9"*H/V[:R7C<HJ]>D813@R_(9X-SX5,29#1N&8(E_*)2$Q&[P,VLE
MY64NEFGU)QOQA;7!@#4,>E TU61#RG$_C;5Q;6;[1.W#@Z/2;,)CRH L9<84
M<,001\@B8#*2($VG,Q(!@,(8W%IC1LL4D2/B% ,6,T>;+SS7&G!- 4]A?%PR
M!EH&,@;L4W&$\>,LYN#'*6SD^O+]QZNS_STS&D3#V?,['@5XB<@C$G(YQ@]?
M:^2>!8LP7K \@: 4TP.V4XZ<:>.:ZH,>'TN3F<8QL8(R-E"?-N0K*/(_EZ\!
M0RW,!"F[WRPW( (SC @D .:@I6!G3#,*Q\$!$V!ZD@S ] 6%4TMI%GW85TC>
MO#P".)+C(OK(?4I6R\./E;J<4/&K"(Y+;%VL\&WYNL%5<=W !0Z=$>J,T%TV
M0B_N(D[>NC-2CO'*-^8/L;V+L\O]A6)ST]2DF;3SW&3TE18F'=-H\[FME*47
M&:7BGD9C8H<VH\@X4M$D &@YEY[CIHZ;[C8W+:E6Q$@QYW+K>"@Z\VSF/K!0
MC$ZE6I,+[S:[5?!KX[K!WBEEDF'/XW3(SGP87))-BFZ6O7?G9_MX\Y7'?I;9
MZ@L-E&>,QDQA%:%/'D-S(^GS)J=SN3@V[-CPCK-AD_C>>M4N#-]/R#'0@5NZ
MQ'3FTU7'A8K>]K'M7/4M[EO>N^IE;Z6J&WB#?O6]RY_V:_FG_C2$]>"GY_LF
M1XX/1#(U%\3(N1]Z*HWY$!EZID;G=TQ5FGAJG%TGP_L%Y4MDQ-$QPT[3=0:=
M?V$#(^9(VPP'L]$#DXPOK5=CYF:5+LHF4%T@_!7>MP)HC4OWK' E=OQD)&-_
M[JYY9\&5572$TN4*<[E=#O'NP.R- 114>&<,3EC<&%.CM)'9#3MAY825$U9.
M6#U.6-V[7+L7:9'ZZHZ'R0B@SD3 -49 QPQXT>7_7&RS)^<!<7;Y4XU=GI=%
ME>.W+K_:Y5=7B0VX_.J-XL'5U-X7EHKJ..W::==5XUV5X50[HEW#+SP9C:8!
MOY-Y='.+M6%\(2F;,PC4+56(M%F+A<,".##PSQ"0"),6V=[[C^C/B4!G]FP.
M9,;?WYV?4=87UF)!1T?)'BE*G%DV+L.B,@-9*0+5;JIL<R/]4$SS5,F]B^N?
MK ?)*Q^/X]<N#VI-;."L5'[R0U%CU=S*ZE07RDX_</J!TP_6F?\T%_=9(H*6
M$$*+T-[1P;;00:_9*?\Y1$)0E:" =6J2[V?*,%Y\O+CZ\?=ZB]6MV=[JSZMZ
M9940U43C7,6JLH&(N7'-U-CE3Z:)S/F<)]M<3](F5[][^N_VK QVA.<(;V<(
M;Y%/BZROS(%61(=R*XON\17DTW'DX\AG1\EG:?E@\D;,IW1K&#7M_R&\Q/B5
M\US-[*ZGHRE'4SM.4]<(!U(#LSHO'X",/"P?R\Z&E&P M)(H6+@MQ$P^QK&@
MJ^&%5.H^1$'.P>(<++O%3';7P3*?J^2$ZB[3P6X*U978>4ZBNA#9.AGU_1;0
M62D<:A-]L;C]4W6A[S0[)]&<9K?6U!H]8I>VR0^Y^@L6\J-M3[H5B39&!'=.
MV=N%;2]K#_6]O,7Z:-^VVKW&,39W#0A45!CT'BMML#<<BQ+ $YBODS6MHQM'
M,W7/2\TTM7GT\>M:L@:,X0P%-67*+_-RWY<V9^C;-O"2?!]]%<?JUJSXG>C'
M*8^GK'5@FR<6Q1'$G>W7Y(M^P@;<LP$BJC4E0H[UXN8ZVRSO#ZH_UR#491$Y
MT>1$TVZ+IJMRD>CS4@G*O:OO^3@Z/=]G%W<1]N;2VR6A[/:HQ%](]?Q(_G1[
MC:.<;6=J_<-=7:GW7VRJ[7W;Z35ZC_E]"V_.2F357DPIGU@>- (3F,<2;\2:
M:H!4L]P^ /;N7)*!IS0P>_LHW;"U%35*%PAF?Z++B0:XRB_J3%FS,^$/ *1H
M^F!Z LZJ4RI.2 4)9ZXZ6-D:B5@K+(Y:CT5 N84T5,T4(.589U0-!EHD6-:<
M@_@K-IN7,:=?.)GE9):36;LMLWX4U+S;\*A2L9R)8'L_$EL_VU:I9;<W+[7
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M!M;DJRMC+[5#E0,,1B/.YC?VLXUE^D]LF@'"^=NCSK0I^!JUJ;Y@*:X=3VR
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M '^ [@L&.S7.+MMO?/$.]50;SPE)@L)7AVJ((!W4#)E[93)_&*<6ZR#D%+7
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MS>NW_[R9,G5[**[WK5'XQ&R(R@;RMC<([PZE@H>RYK2RB@:]G&/MAU]#.(<
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M69?'IM7H/35+S-'(YM#(4]Q4CD8LC;0;W>:C750]HP X']46JBB_T13"KW.
M-Q^*7"%!;44SE28Z 15$AD/G?MID%OHU_+?._]0\Q7YOAYU:Z_!H<VU81\P5
M(^99V=?[&K)O)XC7=E/KU X.CFJ=YA8DP,#_Z'F@E\L(Z[ORNIHK5Z47:4V?
MHZKV^JBJ8I!XB?R:U4'S+;SB7J*K <]"9CC<^GJVR>K@^3Z<")VH>*:CNH/I
M,V&J_IJ.!;L$^V[,'5Q7!=?K1 QXR*YD(*8U=BYCX0'F,C5@[Z_(6'ZKX@B5
M%P&OQN,T!-5WIG73&G2*U>V..419%2CWC@YZ^ZS3:=:/CGHM!]=5P543 39B
M),!_2L/E&IX:5P/"3C79+FS[('S)3QSOWJU3OQ[+9'2M@HEP)[];)_^!)PF[
M%#%W![];![]WW.OLLZ.CP_IQZZ#IX+HJN(Z!H!K8O_:?&IFJ1J9:'76M@C[*
M41Z6C_A0F!A+G0] JSSAP2V?:HK/OW[55_[TA_]\_6J4C(,?_A]02P$"% ,4
M    " !\1'965GPC2<D3  "2W   $0              @ $     :6YZ>2TR
M,#(S,#,R,BYH=&U02P$"% ,4    " !\1'96T*K!:0T#  "A"0  $0
M        @ 'X$P  :6YZ>2TR,#(S,#,R,BYX<V102P$"% ,4    " !\1'96
M)O$2!]P%  !/-@  %0              @ $T%P  :6YZ>2TR,#(S,#,R,E]L
M86(N>&UL4$L! A0#%     @ ?$1V5C*,Z6"N!   \R<  !4
M ( !0QT  &EN>GDM,C R,S S,C)?<')E+GAM;%!+ 0(4 Q0    ( 'U$=E;T
M/ R>YR4   +6 0 /              "  20B  !I;GIY+65X.3E?,2YH=&U0
52P4&      4 !0!! 0  .$@

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
